Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Document › Details

Orchard Therapeutics Ltd.. (12/22/17). "Press Release: Orchard Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference". London.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation Orchard Therapeutics Ltd.
  Group Orchard Therapeutics (Group)
  Organisation 2 J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 36th Annual Healthcare Conference 2018 San Francisco
  Product 2 gene therapy
Index terms Index term Orchard Therapeutics–JPMorgan Chase: investor conference, 201801 supply service Orchard presents at JP Morgan Healthcare Conference 2018
  Index term 2 Orchard Therapeutics–LifeSci: public relations, 201712 service existent by LifeSci Public Relations
Persons Person Rothera, Mark (Orchard Therapeutics 201708– CEO before PTC Therapeutics + Aegerion + Shire Human Genetic Therapies)
  Person 2 Blum, Allison (LifeSci Public Relations 201712)

Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced that Mark Rothera, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 9, 2018 at 3:00 p.m. PT.

About Orchard Therapeutics

Orchard Therapeutics is a privately-held clinical-stage biotechnology company based in the UK and in California, US. Orchard is dedicated to transforming the lives of patients with rare disorders through innovative gene therapies. Orchard works in partnership with some of the world's leading centres in gene therapy, including University College London, Great Ormond Street Hospital for Children NHS Foundation Trust, the University of Manchester and Central Manchester University Hospitals NHS Foundation Trust, the University of California Los Angeles and Boston Children’s Hospital. In 2016 the company was named a Fierce 15 Company by Fierce Biotech. Also, Orchard and UCLA were awarded a $19 million grant from the California Institute of Regenerative Medicine (CIRM) in 2016 to advance the development of autologous ex-vivo lentiviral gene therapy in ADA-SCID.


Corporate contact
Nicolas Koebel
+44 (0) 7717 801246

Media contact
Allison Blum, Ph.D.
LifeSci Public Relations
+1 516 655 0842

Record changed: 2018-01-09


Picture [iito] – Putting Information into Context 600x60px

More documents for Orchard Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top